查詢結果分析
來源資料
相關文獻
- 小細胞肺癌患者接受口服化療合併高劑量維他命C靜脈注射之個案報告
- Importance of Fiberoptic Bronchoscopy Before and During Chemotherapy for Small cell Carcinoma of the Lung in the Evaluation of Complete Remission
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- 維他命C攝取量的基準與建議
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- Inhibition of 2-Aminofluorene Acetylations by Vitamin C in Monouclear Leukocytes of Spregue-Dawley Rats
- 小細胞肺癌的治療
- 我所知道的維他命C
- 維他命C之功能
頁籤選單縮合
題名 | 小細胞肺癌患者接受口服化療合併高劑量維他命C靜脈注射之個案報告=A Patient with Small Cell Lung Cancer Treated with Oral Chemotherapy and Intravenous High Dose Vitamin C |
---|---|
作者姓名(中文) | 林淑娟; 陳明豐; | 書刊名 | 秀傳醫學雜誌 |
卷期 | 6:1/2 民95.04 |
頁次 | 頁13-18 |
分類號 | 415.468 |
關鍵詞 | 小細胞肺癌; 口服etoposiede; 維他命C; 完全緩解; 中位存活期; Small cell lung cancer; Oral etoposide; Vitamin C; Complete remission; Medium survival; |
語文 | 中文(Chinese) |
中文摘要 | 小細胞肺癌為轉移性高的惡性腫瘤,其治療以靜脈注射組合抗癌化學藥物為主,其中又以靜脈注射VP-16(etoposide)合併cisplatin最為常用。對於無法接受靜脈注射化學治療的高齡小細胞肺癌患者而言,如何控制腫瘤的快速成長及轉移常是令臨床醫師頭痛的問題。本文將介紹一個因接受傳統靜脈注射化學藥物、VP-16(etoposide)合併cisplatin導致嚴重副作用的83歲廣範性小細胞肺癌患者。他於改為接受口服etoposide(每日150 mg連續3週,停1週)合併每週靜脈注射高劑量維他命C (50g-60g)四個月後,腫瘤獲得完全緩解,且未出現明顯副作用。患者雖於終止口服etoposise五個月後因腫瘤復發而死亡,但在腫瘤復發前生活機能一直維持在良好狀態,而且其存活期(10個月)仍長於一般單獨接受口服etoposide之廣泛性小細胞肺癌患者的中位存活期(約4.8個月)。此結果顯示,維他命C或許可以加強口服Etoposide的抗癌作用。至於維他命C如何加強化學藥物的抗癌作用值得更進一步探討。 |
英文摘要 | Small cell lung cancer is a kind of canter with high metastasis and mortality rate. The current standard treatment for extensive small cell lung cancer is a combination of chemotherapy with etoposide and cisplatin. While the regimen is highly effective, many older patients could not tolet ate the associated side effects of this regimen and few alternative and effective treatment exists for management of this population of elderly patients. In this teport, we present a case of an 83 year old patient with extensive small cell lung cancer who suffered ft out serious side effects following chemotherapy with intravenous injection of VP-16 and cisplatin and the treatment was switched to oral etoposide (150mg/ day for 3weeks and rest for one week) and intravenous high dose vitamin C (50-60g weekly for 4 months). The tumor responded completely to this regimen and the patient reported no significant side effects. His treatment had continued for 4 months and his performance status had markedly improved and remained stable until 5 months following discontinuation of oral etoposide. His survival period was 10 months, which is significantly longer than the reported median survival of 4.6 months for extensive stage small cell lung cancer treated with oral etoposide aloue. The ability to achieve a complete response and prolonged survival in this patient by this combination therapy suggests that high dose vitamin C may potentiate the cytotoxicity of etoposide in small cell lung cancer. Based on this result, we feel that further investigation into the efficacy of intravenous high dose vitamin C in combination with oral etoposide in the treatment of exensive small lung cancer is warranted. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。